Cancer Research, Oncology R&D, Glaxosmithkline R&D, Collegeville, USA.
J Transl Med. 2011 Jul 25;9:119. doi: 10.1186/1479-5876-9-119.
Globally, gastric cancer is the second most common cause of cancer-related death, with the majority of the health burden borne by economically less-developed countries.
Here, we report a genetic characterization of 50 gastric adenocarcinoma samples, using affymetrix SNP arrays and Illumina mRNA expression arrays as well as Illumina sequencing of the coding regions of 384 genes belonging to various pathways known to be altered in other cancers.
Genetic alterations were observed in the WNT, Hedgehog, cell cycle, DNA damage and epithelial-to-mesenchymal-transition pathways.
The data suggests targeted therapies approved or in clinical development for gastric carcinoma would be of benefit to ~22% of the patients studied. In addition, the novel mutations detected here, are likely to influence clinical response and suggest new targets for drug discovery.
在全球范围内，胃癌是癌症相关死亡的第二大主要原因，大多数健康负担都落在经济欠发达国家身上。
在这里，我们使用 Affymetrix SNP 芯片和 Illumina mRNA 表达芯片以及 Illumina 对属于已知在其他癌症中发生改变的各种途径的 384 个基因的编码区进行测序，报告了 50 例胃腺癌样本的遗传特征。
在 WNT、Hedgehog、细胞周期、DNA 损伤和上皮-间充质转化途径中观察到遗传改变。
数据表明，针对胃癌已批准或正在临床开发的靶向治疗方法可能对研究中的约 22%的患者有益。此外，这里检测到的新突变可能会影响临床反应，并为药物发现提供新的靶点。
